Brostallicin is an investigational drug.
There have been 5 clinical trials for Brostallicin.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Sarcoma, Neoplasms, Plasma Cell, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are European Organisation for Research and Treatment of Cancer - EORTC, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.